5-fluorouracil and alpha-interferon in hepatocellular carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 136-139

  Stuart, Keith ^a,b   Tessitore, Judy ^a   Huberman, Mark ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATAXIA; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I, RECOMBINANT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEUTROPENIA; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0029670249     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00009     Document Type: Article

References (34)

1. Dusheiko G. Hepatocellular carcinoma: molecular biology, etiology and animal models. Gastroenterol Clin North Am 1987;16:575-89.
2. Chung WK, Sun HS, Park DH, Minuk GY, Hoofnagle JH. Primary hepatocellular carcinoma and hepatitis B virus infection in Korea. J Med Virol 1983;11:99-104.
3. Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991;265:1974-6.
4. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992;116:97-102.
5. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma: prevalence and significance. Arch Intern Med 1993;153: 1672-7.
6. Nerenstone S, Friedman M. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 16:603-13.
7. Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
8. Lai ECS, Choi TK, Cheng CH, et al. Doxorubicin for unresectable hepatocellular carcinoma. Cancer 1990;66:1685-7.
9. Lai CL, Wu PC, Chan GCB, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-83.
10. Gastrointestinal Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. Cancer 1990;66:135-9.
11. Lai CL, Lau JYN, Wu PC, et al. Recombinant interferon-α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94.
12. Wadler S, Lyver A, Goldman M, Wiernik PH. Therapy with 5-fluorouracil and recombinant alpha 2a-interferon in refractory GI malignancies. Proc ASCO 1989;8:384.
13. Pazdur R, Abbruzzese J, Faintuch J, et al. Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. Proc ASCO 1990;9:455.
14. Lovett D, Kelsen D, Heelan R, Buckley M, Murray P, Evans L. 5-Fluorouracil and alpha interferon in the treatment of esophageal carcinoma. Proc ASCO 1990;9:471.
15. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alpha 2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
16. Huberman M, Bering H, Tessitore J, Groopman J, Tran L. 5-Fluorouracil plus recombinant alpha interferon in advanced colorectal cancer. Proc ASCO 1990;9:116.
17. Perrillo RP. Treatment of chronic hepatitis B with interferon: experience in western countries. Semin Liver Dis 1989;9: 240-8.
18. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989;321:1501-16.
19. Elias L, Sandoval JM. Interferon's effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1958;163:867-74.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993;72:3202-9.
22. Sarosy GA, Brown TD, Von Hoff DD, et al. Phase I study of α-interferon plus doxorubicin in patients with solid tumors. Cancer Res 1986;46:5368-71.
23. Creagan ET, Frytak S, Long HJ, Kvols LK. Phase I study of recombinant leukocyte α interferon with doxorubicin in advanced malignant disease. Cancer 1989;64:1034-7.
24. Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ. Combined recombinant human alpha interferon and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985;35: 721-9.
25. Miyoshi T, Ogawa S, Kanamori T, et al. Interferon potentiates cytotoxic effects of 5-fluorouracil on cell lines originating from neoplastic tissues. Cancer Lett 1983;17:239-47.
26. Sato M, Yoshida, Urata M, et al. Effects of 5-FU and the combination of 5-FU and IFN on human salivary gland adenocarcinoma cell line in culture. Int J Oral Surg 1984;13:35-44.
27. Le J, Yip Y, Vilcek J. Cytolytic activity of interferon gamma and its synergism with 5-FU. Int J Cancer 1984;34:495-500.
28. Kimoto Y. Combination effect of interferons alpha, beta, and gamma on tumor growth in vitro. Gan To Kagako Ryoho 1986;13:302-7.
29. Kimoto Y. Antitumor effect of interferons with chemotherapeutic agents. Gan To Kagako Ryoho 1986;13:293-301.
30. Grem JL, Jordan E, Robson ME, et al. Phase II study of fluorouracil, leucovorin, and alpha-2a interferon in metastatic colorectal carcinoma. J Clin Oncol 1993;11:1737-45.
31. Nair PV, Tong MJ, Kempf R, Co R, Lee SD, Venturi CL. Clinical, serologic and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma. Cancer 1985;56:1018-22.
32. Sachs E, Di Bisceglie AM, Dusheiko GM, et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer 1985;52:105-10.
33. Lai CL, Wu PC, Lok ASF, Lin HJ, Ngan H. Recombinant alpha interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60: 928-33.
34. Patt Y, Noonan C, Pazdur R, Smith R, Levin B, Yoffe B. Phase II trial of 5-FU and interferon-α in hepatocellular carcinoma. Proc ASCO 1991;10:442.